1-(3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 4-(O-benzyloxime) | 800379-05-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 4-(O-benzyloxime)
• 英文别名: uridine 4-(O-benzyloxime)；1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(phenylmethoxyamino)pyrimidin-2-one
• CAS: 800379-05-9
• 化学式: C₁₆H₁₉N₃O₆
• 分子量: 349.343
• InChiKey: OECIBHXLVJYHLM-NMFUWQPSSA-N

物化性质

• 熔点：
  123-125 °C(Solv: methanol (67-56-1))
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 4-(O-benzyloxime) 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 73.5h， 生成 N⁴-[O-(4-benzyloxy)]-3-methylcytidine-5‘-O-[(phosphonomethyl)phosphonic acid] ditriethylene
  参考文献：
  名称：

  嘌呤和嘧啶核苷酸作为Ecto-5'-核苷酸酶（CD73）抑制剂的结构-活性关系。

  摘要：

  分化簇73（CD73）将5'-单磷酸腺苷转化为免疫抑制腺苷，其抑制作用被提出作为一种新的癌症治疗策略。我们合成了嘌呤和嘧啶核苷的5'-O-[（膦酰基甲基）膦酸]衍生物，它们代表核苷二磷酸类似物，并比较了它们对CD73的抑制作用。在腺嘌呤系列中，大多数核糖修饰和1-deaza和3-deaza都是有害的，但可以容忍7-deaza。耐受尿嘧啶被N3-甲基取代，但不能被较大的基团或2-硫代取代。不容许1，2-二膦酰基-乙基修饰。N4-（芳基）烷氧基-胞嘧啶衍生物，特别是具有庞大的苄氧基取代基的化合物，显示出增强的效力。最有效的抑制剂是5' -5-氟尿苷（4l），N4-苯甲酰基胞苷（7f），N4- [O-（4-苄氧基）]胞苷（9h）和N4- [O的O-[（膦酰基甲基）膦酸]衍生物-（4-萘-2-基甲氧基）]-胞苷（9e）（在人CD73上Ki值为5-10 nM）。在两种尿苷二磷酸激活的P2Y受体亚型上

  DOI：

  10.1021/acs.jmedchem.9b00164
• 作为产物：
  描述：

  3-benzyloxy-1-(3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-4-imino-3,4-dihydropyrimidin-2(1H)-one 在 甲醇 、 lithium hydride 作用下， 生成 1-(3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 4-(O-benzyloxime)
  参考文献：
  名称：

  15 N 3-标记的胞嘧啶核苷的一种新的高效合成方法：胞苷N 3-氧化物的Dimroth重排

  摘要：

  在三个反应步骤中，由苄基溴在过量甲醇甲醇存在下，处理由适当的未保护尿苷制备的15 N 4标记的胞苷N 3-氧化物和15 N 4标记的2'-脱氧胞苷N 3-氧化物即使在温和的条件下，其Dimroth重排的顺利发生也导致相应的15 N 3标记的尿苷4- O-苄基肟，它们很容易经历还原性N - O键断裂，得到所需的15 N 3标记的胞嘧啶核苷具有很高的总收率。

  DOI：

  10.1021/jo0486241

文献信息

• 4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor
  作者：P. Suresh Jayasekara、Matthew O. Barrett、Christopher B. Ball、Kyle A. Brown、Eszter Kozma、Stefano Costanzi、Lucia Squarcialupi、Ramachandran Balasubramanian、Hiroshi Maruoka、Kenneth A. Jacobson

  DOI：10.1039/c3md00132f

  日期：——

  4-Alkyloxyimino derivatives of pyrimidine nucleotides display high potency as agonists of certain G protein-coupled P2Y receptors (P2YRs). In an effort to functionalize a P2Y6R agonist for fluorescent labeling, we probed two positions (N4 and γ-phosphate of cytidine derivatives) with various functional groups, including alkynes for click chemistry. Functionalization of extended imino substituents at the 4 position of the pyrimidine nucleobase of CDP preserved P2Y6R potency generally better than γ-phosphoester formation in CTP derivatives. Fluorescent Alexa Fluor 488 conjugate 16 activated the human P2Y6R expressed in 1321N1 human astrocytoma cells with an EC50 of 9 nM, and exhibited high selectivity for this receptor over other uridine nucleotide-activated P2Y receptors. Flow cytometry detected specific labeling with 16 to P2Y6R-expressing but not to wild-type 1321N1 cells. Additionally, confocal microscopy indicated both internalized 16 (t1/2 of 18 min) and surface-bound fluorescence. Known P2Y6R ligands inhibited labeling. Theoretical docking of 16 to a homology model of the P2Y6R predicted electrostatic interactions between the fluorophore and extracellular portion of TM3. Thus, we have identified the N4-benzyloxy group as a structurally permissive site for synthesis of functionalized congeners leading to high affinity molecular probes for studying the P2Y6R.

  4-烷氧亚氨基嘧啶核苷酸衍生物作为某些G蛋白偶联P2Y受体（P2YRs）的激动剂显示出高度效力。为了对P2Y6R激动剂进行荧光标记，我们在两个位置（胞苷衍生物的N4位和γ-磷酸基团）上探查了包括炔烃在内的各种功能团，用于点击化学反应。在CDP的嘧啶核碱4位上进行扩展亚氨基取代，相比于CTP衍生物中的γ-磷酸酯形成，通常更好地保持了P2Y6R的效力。荧光染料Alexa Fluor 488的共轭物16激活了在1321N1人星形胶质瘤细胞中表达的人P2Y6R，其EC50为9 nM，并且对这种受体的选择性远高于其他由尿嘧啶核苷酸激活的P2Y受体。流式细胞术检测到16对表达P2Y6R的细胞有特异性标记，而对野生型1321N1细胞无标记。此外，共聚焦显微镜显示16被内化（半衰期18分钟）并有表面结合的荧光。已知的P2Y6R配体抑制标记。16与P2Y6R的同源模型的理论对接预测了荧光团与TM3的外部部分之间的静电相互作用。因此，我们确定了N4-苄氧基团作为合成功能化类似物的结构容许位点，从而得到用于研究P2Y6R的高亲和力分子探针。
• Structure-activity relationships of pyrimidine nucleotides containing a 5′-α,β-methylene diphosphonate at the P2Y6 receptor
  作者：Paola Oliva、Mirko Scortichini、Clemens Dobelmann、Shanu Jain、Varun Gopinatth、Kiran S. Toti、Ngan B. Phung、Anna Junker、Kenneth A. Jacobson

  DOI：10.1016/j.bmcl.2021.128137

  日期：2021.8

  highest human P2Y6R potency (MRS4554, 0.57 µM), and a 5-fluoro substitution of the cytosine ring in 28 similarly enhanced potency, with >175- and 39-fold selectivity over human P2Y14R, respectively. However, 3-alkyl (31 – 33, 37, 38), β-D-arabinofuranose (39) and 6-aza (40) substitution prevented P2Y6R activation. Thus, we have identified new α,β -methylene bridged N4-extended CDP analogues as P2Y6R

  G q偶联 P2Y 6受体 (P2Y 6 R) 是嘌呤能信号系统的组成部分，在炎症、心血管和代谢过程中发挥作用。UDP 是天然的 P2Y 6 R 激动剂和 P2Y 14 R 部分激动剂，可被核酸外切酶水解。因此，我们合成了含有稳定α,β-亚甲基桥的UDP/CDP类似物作为P2Y 6 R激动剂，并鉴定了相容的亲和力增强嘧啶修饰。使用 4-苄氧基亚氨基胞苷 5'-二磷酸类似物探索受体上的远端结合区域，并通过钙动员测定测定其效力。25中的 4-三氟甲基-苄氧基亚氨基取代基提供了最高的人 P2Y 6 R 效力（MRS4554，0.57 µM），而28中胞嘧啶环的 5-氟取代基也同样增强了效力，选择性分别比 25 强 175 倍和 39 倍。分别为人 P2Y 14 R。然而，3-烷基 ( 31 – 33 , 37 , 38 )、β-D-阿拉伯呋喃糖 ( 39 ) 和 6-氮杂 ( 40 ) 取代阻止了
• [EN] PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS<br/>[FR] NUCLÉOTIDES DE PURINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE L'ECTO-5'-NUCLÉOTIDASE
  申请人：US HEALTH

  公开号：WO2020037275A1

  公开（公告）日：2020-02-20

  Disclosed is a compound of formula (I), wherein Q, U, T, A, a, b, c, and n are as defined herein. Also disclosed are methods of inhibiting ecto‑5'‑nucleotidase, inhibiting suppression of an antitumor immune response, inhibiting tumor growth of a cancerous tumor, inhibiting metastasis of cancer in a mammal afflicted with cancer, synergistically enhancing a response of a mammal afflicted with cancer undergoing treatment with an immunotherapeutic anti‑cancer agent, potentiating an activity of an inhibitor of nicotinamide phosphoribosyltransferase in a mammal undergoing treatment of a mammal with the inhibitor, and treating preeclampsia in a mammal in need thereof, comprising administering to an animal an effective amount of a compound of formula (I).

  揭示了一种具有式（I）的化合物，其中Q、U、T、A、a、b、c和n的定义如本文所述。还揭示了抑制外源性5'-核苷酸酶、抑制抗肿瘤免疫应答抑制、抑制癌症肿瘤生长、抑制哺乳动物患有癌症的转移、在接受免疫治疗抗癌剂治疗的患有癌症的哺乳动物的反应协同增强、在接受抑制剂治疗的哺乳动物中增强烟酰胺磷酸核糖转移酶的活性、以及治疗患有妊高症的哺乳动物的方法，包括向动物投与式（I）化合物的有效量。
• Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y₆ receptor agonists
  作者：Kiran S. Toti、Shanu Jain、Antonella Ciancetta、Ramachandran Balasubramanian、Saibal Chakraborty、Ryan Surujdin、Zhen-Dan Shi、Kenneth A. Jacobson

  DOI：10.1039/c7md00397h

  日期：——

  modification on the proximal nucleoside that is assumed to bind at the P2Y6R similarly to UDP; (N)-methanocarba was preferred on the distal nucleoside moiety. This suggests that the distal dinucleotide P2Y6R binding site prefers a ribose-like group that can attain a (N) conformation, rather than (S). Dinucleotide binding was modeled by homology modeling, docking and molecular dynamics simulations, which suggested

  UDP激活的P2Y 6受体（P2Y 6 R）的激动剂和拮抗剂已被建议用于治疗，例如癌症，炎症，神经退行性疾病和糖尿病。合成了含有南双环[3.1.0]己烷（（S）-甲氨基甲酸）环系统代替核糖环的尿嘧啶核苷酸，并在钙动员测定中显示为有效的P2Y 6 R激动剂。（S）-甲氨基甲酸酯修饰与嘧啶上的5-碘或4-甲氧基亚氨基相容，但与α，β-亚甲基5'-二磷酸不相容。（S）-Methanocarba二核苷酸效力与假定在P2Y 6结合的近端核苷上的N 4-甲氧基修饰兼容R与UDP类似；在远端核苷部分上优选（N）-甲氨基甲酸酯。这表明远端二核苷酸P2Y 6 R结合位点更喜欢可以达到（N）构象的核糖样基团，而不是（S）。通过同源性建模，对接和分子动力学模拟对二核苷酸结合进行建模，这表明凭经验发现了相同的核糖构象偏好。
• Pyrimidine Nucleotides with 4-Alkyloxyimino and Terminal Tetraphosphate δ-Ester Modifications as Selective Agonists of the P2Y₄ Receptor
  作者：Hiroshi Maruoka、M. P. Suresh Jayasekara、Matthew O. Barrett、Derek A. Franklin、Sonia de Castro、Nathaniel Kim、Stefano Costanzi、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/jm101591j

  日期：2011.6.23

  P2Y(2) and P2Y(4) receptors are G protein-coupled receptors, activated by UTP and dinudeoside tetraphosphates, which are difficult to distinguish pharmacologically for lack of potent and selective ligands. We structurally varied phosphate and uracil moieties in analogues of pyrimidine nucleoside 5'-triphosphates and 5'-tetraphosphate esters. P2Y(4) receptor potency in phospholipase C stimulation in transfected 1321N1 human astrocytoma cells was enhanced in N-4-alkyloxycytidine derivatives. OH groups on a terminal delta-glucose phosphoester of uridine 5'-tetraphosphate were inverted or substituted with H or F to probe H-bonding effects. N-4-(Phenylpropoxy)-CTP 16 (MRS4062), Up(4)-[1]3'-deoxy-3'-fluoroglucose 34 (MRS2927), and N-4-(phenylethoxy)-CTP 15 exhibit >= 10-fold selectivity for human P2Y(4) over P2Y(2) and P2Y(6) receptors (EC50 values 23, 62, and 73 nM, respectively). delta-3-Chlorophenyl phosphoester 21 of Up(4) activated P2Y(2) but not P2Y(4) receptor. Selected nucleotides tested for chemical and enzymatic stability were much more stable than UTP. Agonist docking at CXCR4-based P2Y(2) and P2Y(4) receptor models indicated greater steric tolerance of N-4-phenylpropoxy group at P2Y(4). Thus, distal structural changes modulate potency, selectivity, and stability of extended uridine tetraphosphate derivatives, and we report the first P2Y(4) receptor-selective agonists.